{"id":17647,"date":"2022-06-17T18:02:07","date_gmt":"2022-06-17T12:32:07","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=17647"},"modified":"2023-01-02T10:04:54","modified_gmt":"2023-01-02T04:34:54","slug":"obesity-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape","title":{"rendered":"Obesity: A Worldwide Pandemic with Advancing Management Options"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a31012aa217c\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a31012aa217c\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape\/#How_is_Obesity_Measured\" >How is Obesity Measured?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape\/#Obesity_Epidemiological_Facts_and_Figures\" >Obesity Epidemiological Facts and Figures<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape\/#Obesity_Treatment_Scenario\" >Obesity Treatment Scenario<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape\/#Way_Ahead\" >Way Ahead<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Obesity is a chronic health condition that leads to abnormal or excessive fat accumulation or adipose tissue in the body that presents a health risk. It is an imbalance between calories ingested and calories burned. The factors responsible for the causes of obesity include heredity, a sedentary lifestyle, excessive fat, sugar consumption (energy-dense meals), certain medications, and endocrine issues. Changes in the environment or society, as well as behavior and culture, have a direct influence.<\/p>\n\n\n\n<p>The excess fat around the waist and trunk (abdominal, central, or android obesity) or peripherally around the body (gynoid obesity) can have severe complications. Some studies also concluded that people with higher levels of fat distributed over the body are associated with smaller volumes of important brain structures, including gray matter structures located in the center of the brain.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-is-obesity-measured\"><span class=\"ez-toc-section\" id=\"How_is_Obesity_Measured\"><\/span><strong>How is Obesity Measured?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Among the various methods, the most basic and standard procedure to measure obesity is the body mass index (BMI). BMI considers a person\u2019s weight and height to calculate the level of adiposity. Accordingly, the three <a href=\"https:\/\/www.delveinsight.com\/blog\/obesity-causes-diagnosis-risk-factors-treatment-market\">classes of obesity<\/a> are Overweight (not obese), Class 1 (low-risk),<strong> <\/strong>Class 2 (moderate-risk),<strong> <\/strong>and<strong> <\/strong>Class 3 (high-risk)<strong> <\/strong>obesity. BMI less than <strong>18.5 kg\/m<\/strong><strong><sup>2<\/sup><\/strong> is considered underweight.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174731\/Obesity-1024x475.png\" alt=\"impact of obesity\" class=\"wp-image-17652\" width=\"1024\" height=\"475\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174731\/Obesity-1024x475.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174731\/Obesity-300x139.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174731\/Obesity-150x70.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174731\/Obesity-768x357.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174731\/Obesity-1536x713.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174731\/Obesity-1568x728.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174731\/Obesity.png 1635w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption><strong>Impact of Obesity and associated Disturbances<\/strong><\/figcaption><\/figure>\n\n\n\n<p>On the other hand, if the BMI is between <strong>25 and 30 kg\/m<\/strong><strong><sup>2<\/sup><\/strong>, the person will not be obese but overweight. But if BMI is greater than <strong>30 kg\/m<\/strong><strong><sup>2<\/sup><\/strong>, the person will be under the obese category. Some other methods like <strong>Bioelectric Impedance (BIA), Waist Circumference, Air-displacement Plethysmography, Waist-to-Hip Ratio, Skinfold Thickness<\/strong>, and others are also used to measure obesity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Obesity_Epidemiological_Facts_and_Figures\"><\/span><strong>Obesity Epidemiological Facts and Figures<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The global prevalence of obesity has observed massive growth over the decade and is expected to grow in the coming years. As per data from WHO, obesity has nearly tripled since 1975. According to Delveinsight\u2019s estimates, the United States accounted for approx. <strong>110 million <\/strong>cases of obesity in adults in 2021, followed by <strong>66 million <\/strong>cases in<strong> <\/strong>EU5<strong> <\/strong>and <strong>5.5 million<\/strong> cases in Japanese adults.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-259278b5-6512-4013-b564-acd2881218d8\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.1.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-rfab881-449-\"><rect fill=\"none\" height=\"292\" width=\"424\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-rfab881-453-\"><rect fill=\"none\" height=\"292\" width=\"424\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-rfab881-454-\"><rect fill=\"none\" height=\"292\" width=\"424\" x=\"75\" y=\"71\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"292\" width=\"424\" x=\"75\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 215.5 71 L 215.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 357.5 71 L 357.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 498.5 71 L 498.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 74.5 71 L 74.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 75 363.5 L 499 363.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 305.5 L 499 305.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 246.5 L 499 246.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 188.5 L 499 188.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 129.5 L 499 129.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 70.5 L 499 70.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"292\" width=\"424\" x=\"75\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 75 363.5 L 499 363.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 26.488866806030273 217)\" x=\"26.488866806030273\" y=\"217\">Prevalent cases in million<\/text><path class=\"highcharts-axis-line\" d=\"M 75 71 L 75 363\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-rfab881-453-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(75,71) scale(1 1)\"><rect aria-label=\"US, 110. Prevalent Cases in Million.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"257\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"68\" x=\"36.5\" y=\"35.5\"><\/rect><rect aria-label=\"EU5, 66. Prevalent Cases in Million.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"154\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"68\" x=\"177.5\" y=\"138.5\"><\/rect><rect aria-label=\"Japan, 5.5. Prevalent Cases in Million.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"13\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"68\" x=\"318.5\" y=\"279.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(75,71) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">Obesity Epidemiological Insights<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"52\">Prevalent Cases of Obesity in 2021<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(75,71) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(55,12)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">110<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>110<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(199,115)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">66<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>66<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(339,256)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">5.5<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>5.5<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"145.66666666666333\" y=\"382\">US<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"287.0000000000033\" y=\"382\">EU5<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"428.3333333333333\" y=\"382\">Japan<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"367\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"309\">25<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"250\">50<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"192\">75<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"133\">100<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"75\">125<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Obesity Epidemiology Forecast - 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Obesity Epidemiology Forecast &#8211; 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-rfab881-454-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Obesity Epidemiological Insights\"},\"subtitle\":{\"text\":\"Prevalent Cases of Obesity in 2021\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Prevalent Cases in Million\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Prevalent Cases in Million\\\"\\n\\\"US\\\";110\\n\\\"EU5\\\";66\\n\\\"Japan\\\";5.5\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"Prevalent cases in million\"}}],\"legend\":{\"enabled\":false},\"credits\":{\"text\":\"Obesity Epidemiology Forecast - 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-epidemiology-forecast\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-259278b5-6512-4013-b564-acd2881218d8\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>Moreover, the <a href=\"https:\/\/www.delveinsight.com\/covid19\">COVID-19 pandemic<\/a> also impacted the <a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-epidemiology-forecast\">prevalence of obesity<\/a> positively. The lockdown measures have altered lifestyle patterns, resulting in reduced physical exercise and various other changes in daily actions. Governments and health organizations must devise new methods to combat the growing frequency and raise awareness of the long-term repercussions. However, the stringent regulatory guidelines, the excessive fee for the weight reduction devices, long-time period efficacy, and the side effects related to the pharmacotherapies could be the elements to be addressed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Obesity_Treatment_Scenario\"><\/span><strong>Obesity Treatment Scenario<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Over the years, obesity has changed from being rare to a widespread condition in the developed world. The current pyramid of interventions in the <a href=\"https:\/\/www.delveinsight.com\/blog\/weight-loss-obesity-market\">management of obesity<\/a> includes <strong>diet restriction, diet therapy, physical exercise, anti-obesity drugs, prebiotics, probiotics, bariatric surgery, and cognitive-behavioral strategies.<\/strong> This multifaceted disease has many treatment options; however, these options are not being fully implemented. Despite the upsurge in the market and expenditures on anti-obesity treatments currently available in economically stable areas, obesity is still increasing at epidemic levels.<\/p>\n\n\n\n<p>Surprisingly, various pharmaceutical companies had launched their product in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\">obesity market<\/a> and later got removed by the FDA due to safety-related concerns, such as giving rise to cancer-related diseases. Most of these are related to adverse cardiovascular effects seen in <strong>sibutramine, fenfluramine, dexfenfluramine, rainbow pills<\/strong>, and increased suicidal risk associated with <strong>rimonabant<\/strong>.<\/p>\n\n\n\n<p>In the last century, the pharmacological management of obesity has included <strong>amphetamines, thyroid hormones, dinitrophenol, and various drug combinations (rainbow pills)<\/strong> that were withdrawn shortly after regulatory approval due to serious adverse effects. Several centrally acting sympathomimetics such as <strong>phentermine, cathine, and diethylpropion<\/strong> continue in short\u2010term use. Medicines that have been investigated in weight management include agents as diverse as <strong>mitochondrial uncouplers,<\/strong> <strong>sympathomimetics, serotonergic agonists, lipase inhibitors, cannabinoid receptor antagonists, <\/strong>and<strong> <\/strong>a growing family of gastrointestinal-derived peptides chemically optimized for pharmaceutical use. A sobering realization across most of these approaches is the common inability to achieve placebo-adjusted mean weight loss greater than <strong>10%<\/strong> of initial body weight when chronically administered at tolerable doses.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174909\/Obesity-Treatment-Scenario-1024x498.png\" alt=\"Obesity treatment landscape\" class=\"wp-image-17653\" width=\"1024\" height=\"498\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174909\/Obesity-Treatment-Scenario-1024x498.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174909\/Obesity-Treatment-Scenario-300x146.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174909\/Obesity-Treatment-Scenario-150x73.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174909\/Obesity-Treatment-Scenario-768x374.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174909\/Obesity-Treatment-Scenario-1536x748.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174909\/Obesity-Treatment-Scenario-1568x763.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174909\/Obesity-Treatment-Scenario.png 1664w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption><strong>Evolution of Obesity Treatment <\/strong><\/figcaption><\/figure>\n\n\n\n<p>The story of anti-obesity pharmacotherapy is littered with initially promising drug candidates that were eventually withdrawn because of safety concerns and adverse events that outweigh the modest benefits of treatment. This fate could have also engulfed the new generation of drugs under investigation at the time. However, despite prominent failures of anti-obesity medications, <a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-pipeline-insight\">approved drugs for obesity management<\/a> have been accessible for use in addition to behavior modifications. In the United States and Europe, <strong>orlistat, naltrexone\/bupropion, liraglutide<\/strong>, and, most recently, <strong>semaglutide <\/strong>are registered and promoted. In addition, in the United States, phentermine\/topiramate is even available for long-term use.<\/p>\n\n\n\n<p>These newly FDA-approved obesity drugs changed the <a href=\"https:\/\/www.delveinsight.com\/blog\/obesity-causes-diagnosis-risk-factors-treatment-market\">treatment landscape for obesity<\/a>. In June 2021, the FDA approved once-weekly injectable <strong>Wegovy <\/strong>for chronic weight management in adults with obesity or overweight and at least one weight-related condition. <strong>Semaglutide <\/strong>has a different structure from other GLP-1 receptor agonists; <strong>Saxenda <\/strong>is a once-daily injection approved by the FDA to treat obesity. It prolongs the half-life compared with a daily drug as a weekly agent. <strong>Xenical and Qsymia<\/strong> are the only long-standing product in the obesity market approved many years ago.<\/p>\n\n\n\n<p>Still, patients who are prescribed anti-obesity pharmacotherapy have to face challenges with the exorbitant cost of some of the newer therapeutics, as well as the refusal of many private and public insurers to cover anti-obesity medications. Sometimes patients or their advocates may have success in lobbying their employers to opt into insurance coverage for obesity management. However, for those on Medicare or Medicaid, there is currently absolutely no coverage for anti-obesity medications. Similarly, in EU-5 countries such as France, Italy, Germany, etc., the drugs are not included on the list of reimbursable drugs; social security bodies do not cover that. In this case, the manufacturers\/laboratories are free to set their prices.<\/p>\n\n\n\n<p>There are more effective medications, procedures, and evidence-based <a href=\"https:\/\/www.delveinsight.com\/blog\/weight-loss-obesity-market\">treatments available for obesity<\/a> today than 20 years ago, but health care professionals are still struggling to get treatment for more people. Obesity treatment, in general, is very challenging, partly because it is often not covered by payers. Until 2003, Medicare had an explicit policy that said you could not consider obesity a disease or a health condition. It was considered a cosmetic issue; it was explicitly excluded from any Medicare treatment.<\/p>\n\n\n\n<p>Therefore, patients without coverage are left with the choice of paying out of pocket for a lower-cost generic anti-obesity medication; taking a medication primarily intended for treating other medical conditions such as diabetes or seizures that may also help with weight loss; or, if their BMI and health status is severe enough to satisfy insurance requirements, they may opt for bariatric surgery, a much more widely covered insurance benefit.<\/p>\n\n\n\n<p>However, in the United Kingdom, as per the January 2022 NEWS release from NHS, people struggling to lose weight will now be offered help from their local high street pharmacy as part of the NHS\u2019s radical action to tackle rising obesity levels and type 2 diabetes. Community pharmacy teams can now refer adults living with obesity, and other conditions, to the twelve-week online NHS weight management program. Moreover, in the UK, <strong>Wegovy (semaglutide)<\/strong> is considered a brand new \u2018game-changing\u2019 drug set to make waves in the medical world as thousands of people with obesity in England will be able to access <strong>Wegovy, Semaglutide,<\/strong> on the NHS.<\/p>\n\n\n\n<p>Thinking of obesity as a lifestyle choice rather than disease was more common in the health care community 20 years ago. Some of the prior attitudes toward weight management have changed in the past decade, with more policymakers, providers, and researchers now viewing obesity as one of the top public health concerns in the US. A big part of this change came on June 18, 2013, when AMA issued a new public health policy, stating its recognition of obesity as a disease with multiple pathophysiological aspects requiring a range of interventions to advance weight management treatment and prevention.<\/p>\n\n\n\n<p>A potential way to more generously cover high-value services without raising premiums is to provide less generous coverage of commonly over-used low-value services. In the future, reducing disparities in weight management treatment will require increased reimbursement and expanded coverage for clinically indicated treatment options for patient subgroups for whom the clinical benefits are well established. It is also important to acknowledge that treating obesity leads to preventing or resolving other high-cost chronic conditions, such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-market\">diabetes<\/a>, stroke, and coronary heart disease.<\/p>\n\n\n\n<p><strong>GLP1R agonism<\/strong> establishes a heightened foundation for measuring performance with other entities, and the full depth of its efficacy and the ability to chronically sustain weight loss in multiple populations, many distinct from those in which initial drug registration has occurred, remains to be determined. At the end of 2014, <strong>liraglutide <\/strong>became the first GLP1R agonist to be approved for the treatment of obesity. However, when <strong>semaglutide <\/strong>entered human trials, it caused more than twice as much weight loss as liraglutide, making it the most effective anti-obesity drug ever to gain regulatory approval.<\/p>\n\n\n\n<p>A few key pharma companies are currently pursuing a strategy of targeting more than one brain-acting hormone system at once. The remarkable effectiveness of this strategy in animal models of obesity has contributed to renewed interest in weight loss drugs across the industry. A recent trial conducted by <strong>Eli Lilly<\/strong> suggests that its new diabetes drug, <strong>tirzepatide<\/strong>, which combines the activity of the hormones GLP-1 and gastric inhibitory polypeptide (GIP), may cause more weight loss than semaglutide. Like GLP-1, GIP stimulates insulin secretion around meals, making it an attractive target for weight management.<\/p>\n\n\n\n<p>In particular, according to Delveinsight, <strong>Novo Nordisk\u2019s Semaglutide, Eli Lily &amp; Company\u2019s Tirzepatide,<\/strong> and <strong>Novartis\u2019 Bimagrumab<\/strong> are estimated to have the highest patient share for anti-obesity pharmacotherapy and are likely to have more robust safety profiles than other drugs that have been trialed.<\/p>\n\n\n\n<p><strong>Setmelanotide <\/strong>is a great example of personalizing obesity therapy, albeit with the challenge of identifying a broader population that might benefit from the drug beyond the ultra-rare genetic and syndromic obesities. In contrast, semaglutide has brought us a long way in showing how to affect energy balance by affecting appetite. <strong>Tirzepatide (Phase III) and bimagrumab (Phase II)<\/strong> illustrate what is likely to impact clinical practice.<\/p>\n\n\n\n<p><strong>Tirzepatide <\/strong>has the potential to drive the weight loss market dramatically. It is the first investigational medicine to deliver more than <strong>20%<\/strong> weight loss on average in a <strong>Phase III study,<\/strong> which is as much as can be achieved with successful bariatric surgery. The highest dose of tirzepatide was most effective, resulting in 24 kg of weight loss on average, equivalent to a <strong>22.5%<\/strong> reduction in body weight. In comparison, participants taking the placebo lost just 2 kg on average. Semaglutide also promotes weight loss, but by about <strong>15%<\/strong> on average, suggesting that the added GIP component in tirzepatide gives an extra boost.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/21172555\/Key-events-timeline-for-obesity-drug-1024x409.png\" alt=\"obesity drugs\" class=\"wp-image-17679\" width=\"1024\" height=\"409\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/21172555\/Key-events-timeline-for-obesity-drug-1024x409.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/21172555\/Key-events-timeline-for-obesity-drug-300x120.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/21172555\/Key-events-timeline-for-obesity-drug-150x60.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/21172555\/Key-events-timeline-for-obesity-drug-768x307.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/21172555\/Key-events-timeline-for-obesity-drug-1536x613.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/21172555\/Key-events-timeline-for-obesity-drug-2048x817.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/21172555\/Key-events-timeline-for-obesity-drug-1568x626.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption><strong>Key Developments in the Obesity Treatment Segment<\/strong><\/figcaption><\/figure>\n\n\n\n<p>A new study has confirmed that treatment with <strong>bimagrumab<\/strong>, an antibody that blocks activin type II receptors and stimulates skeletal muscle growth, is safe and effective for treating excess adiposity and metabolic disturbances in adult patients with obesity and <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-2-diabetes-market\">type 2 diabetes<\/a>. These exciting results suggest that there may be a novel mechanism for achieving weight loss with a profound loss of body fat and an increase in lean mass, along with other metabolic benefits.&nbsp;<\/p>\n\n\n\n<p>At the end of the 48-week study, researchers found a nearly 21% decrease in body fat in the bimagrumab group compared to <strong>0.5%<\/strong> in the placebo group. The results also revealed the Bimagrumab group gained <strong>3.6%<\/strong> of lean mass compared with a loss of <strong>0.8%<\/strong> in the placebo group. The combined loss in total body fat and gain in a lean mass led to a net <strong>6.5%<\/strong> reduction in body weight in patients receiving Bimagrumab compared with <strong>0.8%<\/strong> weight loss in their counterparts receiving the placebo.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Way_Ahead\"><\/span><strong>Way Ahead<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In conclusion, the clinical practice of obesity medicine has been a struggle for patients and providers. The <a href=\"https:\/\/www.delveinsight.com\/blog\/weight-loss-obesity-market\">advancement in weight management<\/a> has reached a place where developing some powerful tools is possible. Therefore, the focus can now shift from treating the comorbidity with anti-hypertensives and lipid-lowering drugs to glycemic management drugs.&nbsp;<\/p>\n\n\n\n<p>Moreover, gut hormones may be especially promising candidates for future exploration due to fewer non-specific side effects than centrally acting drugs. It is hoped that weight\u2010loss drugs of the present and future will provide safer and more effective tools for the long\u2010term management of obesity. Today, at the global level, some of the key obesity companies such as <strong>Rhythm Pharmaceuticals, Novo Nordisk, Eli Lilly and Company, Novartis, <\/strong>and<strong> <\/strong>others are involved in developing therapies for obesity. The launch of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-pipeline-insight\">new treatments for obesity<\/a> in the coming years will significantly improve people\u2019s lives affected by obesity.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/02100413\/Obesity-Market-Assesment-and-Forecast-1024x256.png\" alt=\"Obesity Market Assesment and Forecast\" class=\"wp-image-20513\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/02100413\/Obesity-Market-Assesment-and-Forecast-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/02100413\/Obesity-Market-Assesment-and-Forecast-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/02100413\/Obesity-Market-Assesment-and-Forecast-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/02100413\/Obesity-Market-Assesment-and-Forecast-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/02100413\/Obesity-Market-Assesment-and-Forecast-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/02100413\/Obesity-Market-Assesment-and-Forecast-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/02100413\/Obesity-Market-Assesment-and-Forecast.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1655464348739\"><strong class=\"schema-faq-question\"><strong>1. What is obesity?<\/strong><\/strong> <p class=\"schema-faq-answer\">Obesity is a chronic health condition that leads to abnormal or excessive fat accumulation or adipose tissue in the body that presents a health risk. It is an imbalance between calories ingested and calories burned.\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1655464359047\"><strong class=\"schema-faq-question\"><strong>2. What are the causes of obesity?<\/strong><\/strong> <p class=\"schema-faq-answer\">The factors responsible for the causes of obesity include heredity, a sedentary lifestyle, excessive fat, sugar consumption (energy-dense meals), certain medications, and endocrine issues. Changes in the environment or society, as well as behavior and culture, have a direct influence.\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1655464367091\"><strong class=\"schema-faq-question\"><strong>3. What are the symptoms of obesity?<\/strong><\/strong> <p class=\"schema-faq-answer\">Obesity symptoms extend beyond increased body fat. It can cause skin problems, shortness of breath, difficulty sleeping, and other symptoms. Some symptoms are even known to raise a person's likelihood of developing certain diseases and disorders. These can be life-threatening or even fatal in some situations.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1655464376519\"><strong class=\"schema-faq-question\"><strong>4. Which pharma companies are working in the obesity market?<\/strong><\/strong> <p class=\"schema-faq-answer\">Today, at the global level, some of the key obesity companies such as Rhythm Pharmaceuticals, Novo Nordisk, Eli Lilly and Company, Novartis, and others are involved in developing therapies for obesity.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Obesity is a chronic health condition that leads to abnormal or excessive fat accumulation or adipose tissue in the body that presents a health risk. It is an imbalance between calories ingested and calories burned. The factors responsible for the causes of obesity include heredity, a sedentary lifestyle, excessive fat, sugar consumption (energy-dense meals), certain [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":17651,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1173,19429,19427,18881,19428,19430],"industry":[17225],"therapeutic_areas":[18720],"class_list":["post-17647","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-obesity","tag-obesity-companies","tag-obesity-management","tag-obesity-market","tag-obesity-prevalence","tag-obesity-treatment","industry-pharmaceutical","therapeutic_areas-nutritional-disorders-and-weight-loss"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Evolving Obesity Treatment - Emerging Therapies and Key Companies<\/title>\n<meta name=\"description\" content=\"Over the years, obesity has changed from being a rare to a widespread condition in the developed world. Companies in obesity treatment market\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evolving Obesity Treatment - Emerging Therapies and Key Companies\" \/>\n<meta property=\"og:description\" content=\"Over the years, obesity has changed from being a rare to a widespread condition in the developed world. Companies in obesity treatment market\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-17T12:32:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-02T04:34:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174553\/obesity-treatment-landscape.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Evolving Obesity Treatment - Emerging Therapies and Key Companies","description":"Over the years, obesity has changed from being a rare to a widespread condition in the developed world. Companies in obesity treatment market","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"Evolving Obesity Treatment - Emerging Therapies and Key Companies","og_description":"Over the years, obesity has changed from being a rare to a widespread condition in the developed world. Companies in obesity treatment market","og_url":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-06-17T12:32:07+00:00","article_modified_time":"2023-01-02T04:34:54+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174553\/obesity-treatment-landscape.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape","name":"Evolving Obesity Treatment - Emerging Therapies and Key Companies","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174553\/obesity-treatment-landscape.png","datePublished":"2022-06-17T12:32:07+00:00","dateModified":"2023-01-02T04:34:54+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Over the years, obesity has changed from being a rare to a widespread condition in the developed world. Companies in obesity treatment market","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#faq-question-1655464348739"},{"@id":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#faq-question-1655464359047"},{"@id":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#faq-question-1655464367091"},{"@id":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#faq-question-1655464376519"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174553\/obesity-treatment-landscape.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174553\/obesity-treatment-landscape.png","width":772,"height":482,"caption":"obesity-treatment-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#faq-question-1655464348739","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#faq-question-1655464348739","name":"1. What is obesity?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Obesity is a chronic health condition that leads to abnormal or excessive fat accumulation or adipose tissue in the body that presents a health risk. It is an imbalance between calories ingested and calories burned.\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#faq-question-1655464359047","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#faq-question-1655464359047","name":"2. What are the causes of obesity?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The factors responsible for the causes of obesity include heredity, a sedentary lifestyle, excessive fat, sugar consumption (energy-dense meals), certain medications, and endocrine issues. Changes in the environment or society, as well as behavior and culture, have a direct influence.\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#faq-question-1655464367091","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#faq-question-1655464367091","name":"3. What are the symptoms of obesity?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Obesity symptoms extend beyond increased body fat. It can cause skin problems, shortness of breath, difficulty sleeping, and other symptoms. Some symptoms are even known to raise a person's likelihood of developing certain diseases and disorders. These can be life-threatening or even fatal in some situations.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#faq-question-1655464376519","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape#faq-question-1655464376519","name":"4. Which pharma companies are working in the obesity market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Today, at the global level, some of the key obesity companies such as Rhythm Pharmaceuticals, Novo Nordisk, Eli Lilly and Company, Novartis, and others are involved in developing therapies for obesity.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/17174553\/obesity-treatment-landscape-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity management<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Obesity Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity prevalence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">obesity<\/span>","<span class=\"advgb-post-tax-term\">obesity companies<\/span>","<span class=\"advgb-post-tax-term\">obesity management<\/span>","<span class=\"advgb-post-tax-term\">Obesity Market<\/span>","<span class=\"advgb-post-tax-term\">obesity prevalence<\/span>","<span class=\"advgb-post-tax-term\">obesity treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jun 17, 2022","modified":"Updated on Jan 2, 2023"},"absolute_dates_time":{"created":"Posted on Jun 17, 2022 6:02 pm","modified":"Updated on Jan 2, 2023 10:04 am"},"featured_img_caption":"obesity-treatment-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=17647"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17647\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/17651"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=17647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=17647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=17647"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=17647"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=17647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}